Improving vascular function in hypertension: Potential benefits of combination therapy with amlodipine and renin-angiotensin-aldosterone system blockers

Journal of Hypertension

Volumn 28, Issue 1, 2010, Pages 2-8

  Siragy, Helmy M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Amlodipine; Angiotensin; AT1 receptor; Endothelial function; Hypertension; Nitric oxide; Reninangiotensinaldosterone system

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ATENOLOL; BENAZEPRIL; BENAZEPRILAT; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; LISINOPRIL; LOSARTAN; NITRIC OXIDE; RAMIPRIL; RAMIPRILAT; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COUGHING; DIZZINESS; DRUG DOSE TITRATION; DRUG POTENTIATION; EDEMA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FLUSHING; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MICROCIRCULATION; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SYNCOPE; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; VASODILATATION;

EID: 73849086461     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328332bcf0     Document Type: Review

References (62)

1. Münzel T, Sinning C, Post F, Warnholtz A, Schultz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2008; 40:180-196.
2. Mason RP. A rationale for combination therapy in risk factor management: a mechanistic perspective. Am J Med 2005; 118:54S-61S.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
4. Turnbull F, Neal B, Algert C, Chalmers J, Woodward M, MacMahon S. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
5. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336:1121-1123.
6. Mason RP. Mechanisms of atherosclerotic plaque stabilization for the lipophilic calcium antagonist amlodipine. Am J Cardiol 2001; 88:2M-6M.
7. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr Hypertens Rep 2000; 2:64-70.
8. 2\+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species. Atherosclerosis 2007; 195:39-47.
9. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
10. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists. Ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003; 23:2155-2163.
11. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002; 62:265-284. (Pubitemid 34169434)
12. Ghiadoni L,Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41:1281-1286.
13. Mohler ER 3rd, Herrington D,Ouyang P, Mangano C, Ritter S, Davis P, et al. A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure. J Clin Hypertens 2006; 8:692-698.
14. Hirooka Y, Kimura Y, Sagara Y, Ito K, Sunagawa K. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens 2008; 30:267-276.
15. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GBJ, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102:1503-1510.
16. Jorgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, Hansen J, et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 2000; 35:592-599.
17. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292:2217-2226.
18. Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a b-blocker. Am J Hypertens 1995; 8:229-236.
19. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101:1653-1659.
20. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001; 103:799-805.
21. Rizzoni D, Muiesan ML, Porteri E, Castellano M, Zulli R, Bettoni G, et al. Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J Hypertens 1997; 15:197-204.
22. Ichihara A, Kaneshiro Y, Sakoda M, Takemitsu T, Itoh H. Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin receptor blocker. J Cardiovasc Pharmacol 2007; 49:161-166.
23. Neutel JM, Smith DH, Weber MA. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens 2004; 17:37-42.
24. Versari D, Virdis A, Ghiadoni L, Daghini E, Duranti E, Masi S, et al. Effect of verapamil, trandolapril and their combination on vascular function and structure in essential hypertensive patients. Atherosclerosis 2009; 205:214-220.
25. Loke KE, Messina EJ, Shesely EG, Kaley G, Hintze TH. Potential role of eNOS inthe therapeutic control of myocardial oxygen consumption byACE inhibitors and amlodipine. Cardiovasc Res 2001; 49:86-93.
26. G-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Hypertens Res 2005; 28:689-700.
27. Kobayashi N, Yanaka H, Tojo A, Kobayashi K, Matsuoka H. Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats. J Cardiovasc Pharmacol 1999; 34:173-181.
28. Lob H, Rosenkranz AC, Breitenbach T,Berkels R, Drummond G, Roesen R. Antioxidant and nitric oxide-sparing actions of dihydropyridines and ACE inhibitors differ in human endothelial cells. Pharmacology 2006; 76:8-18.
29. Rosenkranz AC, Lob H, Breitenbach T, Berkels R, Roesen R. Endothelial antioxidant actions of dihydropyridines and angiotensin converting enzyme inhibitors. Eur J Pharmacol 2006; 529:55-62. (Pubitemid 43005285)
30. Walter MF, Jacob RF, Jeffers B, Ghadanfar MM, Preston GM, Buch J, et al. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease. A longitudinal analysis of the PREVENT study. J Am Coll Cardiol 2004; 44:1996-2002.
31. Mason RP. Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific research. Cerebrovasc Dis 2003; 16:11-17.
32. Toba H, Shimizu T, Miki S, Inoue R, Yoshimura A, Tsukamoto R, et al. Calcium channel blockers reduce angiotensin II-induced superoxide generation and inhibit lectin-like oxidized low-density lipoprotein receptor-1 expression in endothelial cells. Hypertens Res 2006; 29:105-116.
33. Zhou MS, Jaimes EA, Raij L. Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats. Am J Hypertens 2004; 17:167-171.
34. Phillips JE, Mason RP. Inhibition of oxidized LDL aggregation with the calcium channel blocker amlodipine: role of electrostatic interactions. Atherosclerosis 2003; 168:239-244.
35. Muda P, Kampus P, Teesalu R, Zilmer K, Ristimäe T, Fischer K, Zilmer M. Effects of amlodipine and candesartan on oxidized LDL level in patients with mild to moderate essential hypertension. Blood Press 2006; 15:313-318.
36. Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005; 27:578-587.
37. Schölkens BA, Landgraf W. ACE inhibition and atherogenesis. Can J Physiol Pharmacol 2002; 80:354-359.
38. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. Circ Res 2000; 87:840-844.
39. Pecháňová O, Simko F. The role of nitric oxide in the maintenance of vasoactive balance. Physiol Res 2007; 56:S7-S16.
40. Jiang F, Drummond GR, Dusting GJ. Suppression of oxidative stress in the endothelium and vascular wall. Endothelium 2004; 11:79-88.
41. 2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997; 100:264-269.
42. 2-receptor-null mice. Hypertension 2003; 42:600-604.
43. 1 receptor blockade. J Hypertens 2004; 22:1571-1577.
44. 2 production in conscious rats. J Clin Invest 1996; 97:1978-1982.
45. Landmesser U, Drexler H. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens Suppl 2006; 24:S39-S43.
46. Zhang X-P, Xu X, Nasjletti A, Hintze TH. Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels. J Cardiovasc Pharmacol 2000; 35:195-202.
47. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95:1115-1118.
48. Witherow FN, Helmy A, Webb DJ, Fox KAA, Newby DE. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 2001; 104:2177-2181.
49. Siragy HM, Awad A, Abadir P, Webb R. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-a in diabetic rats. Endocrinology 2003; 144:2229-2233.
50. Siragy HM, de Gasparo M, El-Kersh M, Carey RM. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 2001; 38:183-186.
51. Lüscher TF, Wenzel RR, Moreau P,Takase H. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardiovasc Drugs Ther 1995; 9 (Suppl 3):509-523.
52. Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-a production after cardiac ischemia. J Cardiovasc Pharmacol 2006; 47:636-642.
53. Mital S, Loke KE, Slater JP, Addonizio L, Gersony WM, Hintze TH. Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human hearts. Am J Cardiol 1999; 83:92H-98H.
54. Kribbs SB, Merritt WM, Clair MJ, Krombach S, Houck WV, Dodd MG, et al. Amlodipine monotherapy, angiotensin-converting enzyme inhibition, and combination therapy with pacing-induced heart failure. Hypertension 1998; 31:755-765.
55. Ferri C, Croce G, Desideri G. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine. Adv Ther 2008; 25:300-320.
56. Donati L, Bü hler FR, Beretta-Piccoli C, Kusch F, Heinen G. Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II. Clin Pharmacol Ther 1992; 52:50-59.
57. Garcha RS, Sever PS, Hughes AD. Mechanism of action of angiotensin II in human isolated subcutaneous resistance arteries. Br J Pharmacol 2001; 134:188-196.
58. Arun KH, Kaul CL, Ramarao P. AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats. Cardiovasc Res 2005; 65:374-386.
59. Raicu M, Pojoga L, Simionescu N, Simionescu M. The effect of ACE inhibitors on atheroma formation is potentiated by association with a calcium channel blocker. A biochemical and ultrastructural study. J Submicrosc Cytol Pathol 1997; 29:317-328.
60. Terpstra WF, May JF, Smit AJ, de Graeff PA, Havinga TK, van den Veur E, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001; 19:303-309.
61. Fogari R, Preti P, Zoppi A, Rinaldi A, Corradi L, Pasotti C, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15:1042-1049.
62. Ohbayashi Y, Tsutamoto T, Sakaguchi T, Tanaka T, Kanamori T, Yokohama H, et al. Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine. J Cardiovasc Pharmacol 2003; 42 (Suppl 1):s71-s74.